Search Results

You are looking at 111 - 120 of 294 items for :

  • "Neoadjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Part 1: Abstracts from the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™

whether CT chest, CT abdomen/pelvis, PET scan, bone scan, and brain imaging studies were ordered; reason for ordering them; and the time to first treatment with either neoadjuvant chemotherapy or surgery. Results: At least one staging study was ordered

Full access

Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer

Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg, and Gregory A. Vidal

ductal carcinoma of the breast in 2007. She received neoadjuvant chemotherapy with dose-dense doxorubicin, cyclophosphamide, and paclitaxel, and subsequently underwent a lumpectomy and axillary lymph node dissection showing residual carcinoma. After whole

Full access

Bone Cancer

J. Sybil Biermann, Douglas R. Adkins, Robert S. Benjamin, Brian Brigman, Warren Chow, Ernest U. Conrad III, Deborah A. Frassica, Frank J. Frassica, Suzanne George, Kenneth R. Hande, Francis J. Hornicek, G. Douglas Letson, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Neeta Somaiah, and Alan W. Yasko

neoadjuvant chemotherapy in cooperative study group protocols, axial tumor site, male gender, and a long history of symptoms were associated with poor response to chemotherapy. Patient age and tumor location at diagnosis had a significant influence on outcome

Full access

Treatment of Locally Advanced/Metastatic Colorectal Cancer

Presented by: Alan P. Venook and Christopher G. Willett

. Conroy T , Bosset JF , Etienne PL , . Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3

Full access

Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505

Jordan M. Cloyd, Sarah Colby, Katherine A. Guthrie, Andy M. Lowy, E. Gabrielle Chiorean, Phillip Philip, Davendra Sohal, and Syed Ahmad

Clinical Trials Network, comparing 2 neoadjuvant chemotherapy regimens among patients with resectable PDAC. Patients were eligible if they had histologic or cytologic confirmed disease, no evidence of metastatic disease, Zubrod PS of 0 or 1, between ≥18 and

Full access

Multimodality Approaches for the Curative Treatment of Esophageal Cancer

Raymond Jang, Gail Darling, and Rebecca K.S. Wong

carcinoma . Chin Med J (Engl) 2013 ; 126 : 3138 – 3145 . 15. Kumagai K Rouvelas I Tsai JA . Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable

Full access

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns, and Miranda Hughes

chemotherapy followed by interval cytoreduction remains controversial for epithelial ovarian cancer. 94 – 101 Neoadjuvant chemotherapy may be considered (category 1) for patients with bulky stage III to IV disease who are not surgical candidates; however, a

Full access

Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, Rachel Clark, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

greater cervical cancers. Abroad, select FIGO IB2 to IIB cases may be treated with radical hysterectomy or neoadjuvant chemotherapy followed by radical hysterectomy. For recurrent or persistent cervical cancers that are confined to the central pelvis (ie

Full access

The Management of Patients With Stage IIIA Non–Small Cell Lung Cancer With N2 Mediastinal Node Involvement

Renato G. Martins, Thomas A. D’Amico, Billy W. Loo Jr, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng-Ming (Spring) Kong, Mark G. Kris, Inga T. Lennes, and Douglas E. Wood

tolerate the toxicities of cisplatin, no data are available to adequately guide therapy. A total of 755 patients were treated in 11 trials assessing neoadjuvant chemotherapy, and 627 patients were treated in 11 trials assessing concurrent CRT. The overall

Full access

Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Vicki Keedy, Edward Kim, Henry Koon, Joel Mayerson, Martin McCarter, Sean V. McGarry, Christian Meyer, Zachary S. Morris, Richard J. O'Donnell, Alberto S. Pappo, I. Benjamin Paz, Ivy A. Petersen, John D. Pfeifer, Richard F. Riedel, Bernice Ruo, Scott Schuetze, William D. Tap, Jeffrey D. Wayne, Mary Anne Bergman, and Jillian L. Scavone

associated with a major survival benefit for patients with high-grade tumors. 71 Histotype-specific neoadjuvant chemotherapy was examined in a recent international randomized controlled trial of patients with high-risk STS (n=287; ISG-STS, 1001). 72